Cases of laboratory-confirmed SARS-CoV-2 reinfection have been reported in a number of
countries. Further, the level of natural immunity induced by SARS-CoV-2 infection is not fully …

The 2019 novel coronavirus (2019-nCoV, now designated as severe acute respiratory
syndrome coronavirus 2, SARS-CoV-2) outbreak has posed a severe threat to public health …

More than a year after the start of the pandemic, COVID-19 remains a global health
emergency. Although the immune response against SARS-CoV-2 has been extensively …

After a short recovery period, COVID-19 reinfections could occur in convalescent patients,
even those with measurable levels of neutralizing antibodies. Effective vaccinations and …

Following acute infection, individuals COVID-19 may still shed SARS-CoV-2 RNA. However,
limited information is available regarding the active shedding period or whether infectious …

We followed–up a mild COVID-19 patient for 91 days and serially monitored his serum
antibodies to four SARS-CoV-2 related antigens (NP, RBD, S1 and ECD) and neutralization …

In March 2020, mild signs and symptoms of coronavirus disease developed in a healthy 33-
year-old man in Hong Kong. His first infection did not produce virus neutralizing antibodies …

Objectives To investigate serological differences between SARS-CoV-2 reinfection cases
and contemporary controls, to identify antibody correlates of protection against reinfection …

In order to support vaccine development, and to aid convalescent plasma therapy, it would
be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing …

To assess the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) antibodies produced by natural infection and describe the serological characteristics over …